Enzymatic properties and clinical associations of serum alpha‐galactosidase A in Parkinson's disease

Recent studies have revealed an association between Parkinson's disease (PD) and Fabry disease, a lysosomal storage disorder; however, the underlying mechanisms remain to be elucidated. This study aimed to investigate the enzymatic properties of serum alpha‐galactosidase A (GLA) and compared them with the clinical parameters of PD.

[1]  Huifu Wang,et al.  Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy , 2023, npj Parkinson's Disease.

[2]  Peter Lansbury.  The Sphingolipids Clearly Play a Role in Parkinson's Disease, but Nature Has Made it Complicated , 2022, Movement disorders : official journal of the Movement Disorder Society.

[3]  X. Han,et al.  A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes , 2022, Frontiers in Neuroscience.

[4]  H. Houlden,et al.  Prevalence of Fabry Disease among Patients with Parkinson's Disease , 2022, Parkinson's disease.

[5]  J. Ferreira,et al.  Frequency of dementia in Parkinson's disease: A systematic review and meta-analysis , 2021, Journal of the Neurological Sciences.

[6]  Wei Liu,et al.  α-Synuclein aggregation in the olfactory bulb induces olfactory deficits by perturbing granule cells and granular–mitral synaptic transmission , 2021, NPJ Parkinson's disease.

[7]  J. Trojanowski,et al.  Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease , 2021, Movement disorders : official journal of the Movement Disorder Society.

[8]  Bin Liu,et al.  Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease , 2021, Journal of Neuroimmunology.

[9]  P. Svenningsson,et al.  A multicentre validation study of the diagnostic value of plasma neurofilament light , 2021, Nature Communications.

[10]  Can Kayatekin,et al.  Murine Models of Lysosomal Storage Diseases Exhibit Differences in Brain Protein Aggregation and Neuroinflammation , 2021, Biomedicines.

[11]  C. Klein,et al.  Mitochondria and Parkinson’s Disease: Clinical, Molecular, and Translational Aspects , 2020, Journal of Parkinson's disease.

[12]  B. Bloem,et al.  Reader response: Blood NfL: A biomarker for disease severity and progression in Parkinson disease , 2020, Neurology.

[13]  N. Keong,et al.  Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson’s disease , 2020, Molecular Neurodegeneration.

[14]  J. Kulisevsky,et al.  Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease. , 2020, Parkinsonism & related disorders.

[15]  B. Mollenhauer,et al.  Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide , 2020, Movement disorders clinical practice.

[16]  H. Braak,et al.  Fabry Disease With Concomitant Lewy Body Disease , 2019, Journal of neuropathology and experimental neurology.

[17]  K. Shedden,et al.  Measures of Cystic Fibrosis Airway Microbiota during Periods of Clinical Stability. , 2019, Annals of the American Thoracic Society.

[18]  D. Priestman,et al.  Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease , 2019, Molecular Neurodegeneration.

[19]  D. Surmeier,et al.  Increased Lysosomal Exocytosis Induced by Lysosomal Ca2+ Channel Agonists Protects Human Dopaminergic Neurons from α-Synuclein Toxicity , 2019, The Journal of Neuroscience.

[20]  J. Bereiter-Hahn,et al.  Age-related dysfunction of the autophago-lysosomal pathway in human endothelial cells , 2019, Pflügers Archiv - European Journal of Physiology.

[21]  N. Hattori,et al.  Altered regulation of serum lysosomal acid hydrolase activities in Parkinson's disease: A potential peripheral biomarker? , 2019, Parkinsonism & related disorders.

[22]  W. Chung,et al.  Alpha galactosidase A activity in Parkinson's disease , 2018, Neurobiology of Disease.

[23]  Jianhua Zhang,et al.  The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson's disease brain in association with the pathologic accumulation of alpha-synuclein , 2018, Neurobiology of Disease.

[24]  Simon C. Potter,et al.  Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease , 2017, Brain : a journal of neurology.

[25]  R. Desnick,et al.  Parkinson's disease prevalence in Fabry disease: A survey study , 2017, Molecular genetics and metabolism reports.

[26]  R. Barker,et al.  Dermal fibroblasts from patients with Parkinson’s disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations , 2017, F1000Research.

[27]  P. Calabresi,et al.  Cerebrospinal fluid β‐glucocerebrosidase activity is reduced in parkinson's disease patients , 2017, Movement disorders : official journal of the Movement Disorder Society.

[28]  R. Nixon,et al.  Disorders of lysosomal acidification—The emerging role of v-ATPase in aging and neurodegenerative disease , 2016, Ageing Research Reviews.

[29]  S. Orimo,et al.  123I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α-synucleinopathies , 2016, Ageing Research Reviews.

[30]  Kenichi Nakajima,et al.  Normal values and standardization of parameters in nuclear cardiology: Japanese Society of Nuclear Medicine working group database , 2016, Annals of Nuclear Medicine.

[31]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[32]  O. Isacson,et al.  Progressive decline of glucocerebrosidase in aging and Parkinson's disease , 2015, Annals of Clinical and Translational Neurology.

[33]  F. Shibasaki,et al.  Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease , 2014, Molecular genetics and metabolism reports.

[34]  E. Bézard,et al.  Lysosomal impairment in Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[35]  L. Schöls,et al.  CSF Aβ42 and tau in Parkinson's disease with cognitive impairment , 2010, Movement disorders : official journal of the Movement Disorder Society.

[36]  T. Kanekura,et al.  Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease. , 2009, American journal of human genetics.

[37]  B. Yan,et al.  Decreased activities of lysosomal acid alpha-D-galactosidase A in the leukocytes of sporadic Parkinson's disease , 2008, Journal of the Neurological Sciences.

[38]  E. Tolosa,et al.  Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force , 2007, Movement disorders : official journal of the Movement Disorder Society.

[39]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[40]  K. Williams,et al.  Human Vascular Endothelial Cells Are a Rich and Regulatable Source of Secretory Sphingomyelinase , 1998, The Journal of Biological Chemistry.

[41]  D. Stuss,et al.  Do long tests yield a more accurate diagnosis of dementia than short tests? A comparison of 5 neuropsychological tests. , 1996, Archives of neurology.

[42]  R. Barker,et al.  Dermal fibroblasts from patients with Parkinson's disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations. , 2017, F1000Research.

[43]  P. Calabresi,et al.  Cerebrospinal Fluid b-Glucocerebrosidase Activity Is Reduced in Parkinson ’ s Disease Patients , 2017 .

[44]  T. Kobayakawa,et al.  Smell identification in Japanese Parkinson's disease patients: using the odor stick identification test for Japanese subjects. , 2008, Internal medicine.